Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q99622
UPID:
C10_HUMAN
Alternative names:
-
Alternative UPACC:
Q99622; B2R4Q6
Background:
Protein C10 plays a pivotal role in the development of the brain, particularly in the formation of the corpus callosum, a critical structure facilitating communication between the brain's hemispheres. Its precise mechanisms and interactions within the brain remain a subject of ongoing research, highlighting its complex involvement in neural development.
Therapeutic significance:
Linked to Temtamy syndrome, a condition characterized by intellectual disability and craniofacial dysmorphism, Protein C10's genetic variants suggest a direct impact on its function. Understanding the role of Protein C10 could open doors to potential therapeutic strategies, offering hope for targeted interventions in genetic disorders affecting brain development.